X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DIVIS LABORATORIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DIVIS LABORATORIES TORRENT PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 45.5 34.1 133.4% View Chart
P/BV x 6.2 6.6 93.2% View Chart
Dividend Yield % 0.8 0.7 122.5%  

Financials

 TORRENT PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
DIVIS LABORATORIES
Mar-18
TORRENT PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,5501,142 135.8%   
Low Rs1,144533 214.5%   
Sales per share (Unadj.) Rs354.7146.6 242.0%  
Earnings per share (Unadj.) Rs40.133.0 121.3%  
Cash flow per share (Unadj.) Rs64.238.4 167.2%  
Dividends per share (Unadj.) Rs14.0010.00 140.0%  
Dividend yield (eoy) %1.01.2 87.1%  
Book value per share (Unadj.) Rs273.1222.8 122.6%  
Shares outstanding (eoy) m169.22265.47 63.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.85.7 66.5%   
Avg P/E ratio x33.625.3 132.6%  
P/CF ratio (eoy) x21.021.8 96.2%  
Price / Book Value ratio x4.93.8 131.2%  
Dividend payout %34.930.3 115.4%   
Avg Mkt Cap Rs m227,897222,318 102.5%   
No. of employees `00014.710.8 136.6%   
Total wages/salary Rs m11,3534,561 248.9%   
Avg. sales/employee Rs Th4,083.03,616.0 112.9%   
Avg. wages/employee Rs Th772.3423.8 182.2%   
Avg. net profit/employee Rs Th461.3814.9 56.6%   
INCOME DATA
Net Sales Rs m60,02138,915 154.2%  
Other income Rs m2,9881,134 263.4%   
Total revenues Rs m63,00940,049 157.3%   
Gross profit Rs m13,49312,617 106.9%  
Depreciation Rs m4,0861,425 286.8%   
Interest Rs m3,08513 23,194.0%   
Profit before tax Rs m9,31012,313 75.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5293,543 71.4%   
Profit after tax Rs m6,7818,770 77.3%  
Gross profit margin %22.532.4 69.3%  
Effective tax rate %27.228.8 94.4%   
Net profit margin %11.322.5 50.1%  
BALANCE SHEET DATA
Current assets Rs m52,62345,351 116.0%   
Current liabilities Rs m52,0226,507 799.4%   
Net working cap to sales %1.099.8 1.0%  
Current ratio x1.07.0 14.5%  
Inventory Days Days120127 94.4%  
Debtors Days Days7695 80.1%  
Net fixed assets Rs m85,01621,160 401.8%   
Share capital Rs m846531 159.4%   
"Free" reserves Rs m45,37658,625 77.4%   
Net worth Rs m46,22259,156 78.1%   
Long term debt Rs m41,1150-   
Total assets Rs m142,43267,832 210.0%  
Interest coverage x4.0926.8 0.4%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.40.6 73.5%   
Return on assets %6.912.9 53.5%  
Return on equity %14.714.8 99.0%  
Return on capital %14.220.8 68.1%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m14,58032,359 45.1%   
Fx outflow Rs m3,6009,042 39.8%   
Net fx Rs m10,98023,317 47.1%   
CASH FLOW
From Operations Rs m8,9427,759 115.3%  
From Investments Rs m-47,070-4,783 984.1%  
From Financial Activity Rs m34,174-3,142 -1,087.8%  
Net Cashflow Rs m-3,655-166 2,201.8%  

Share Holding

Indian Promoters % 71.5 52.0 137.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.8 59.5%  
FIIs % 12.6 19.0 66.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.2 51.2%  
Shareholders   26,511 31,796 83.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  MERCK LTD  NOVARTIS  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Dec 11, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS